{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T06:00:55Z","timestamp":1766901655975,"version":"3.48.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004410","name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ft\u0131rma Kurumu","doi-asserted-by":"publisher","award":["121S986&323S070"],"award-info":[{"award-number":["121S986&323S070"]}],"id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11033-025-10834-3","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T18:13:39Z","timestamp":1752776019000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Brigimadlin (BI-907828) and napabucasin (BBI608) cooperatively trigger apoptosis in chronic lymphocytic leukemia cells by simultaneous inhibition of MDM2 and STAT3"],"prefix":"10.1007","volume":"52","author":[{"given":"Erhan","family":"Aptullahoglu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"key":"10834_CR1","doi-asserted-by":"crossref","first-page":"1371057","DOI":"10.3389\/fonc.2024.1371057","volume":"14","author":"J Braish","year":"2024","unstructured":"Braish J, Cerchione C, Ferrajoli A (2024) An overview of prognostic markers in patients with CLL. Front Oncol 14:1371057","journal-title":"Front Oncol"},{"key":"10834_CR2","doi-asserted-by":"crossref","unstructured":"Fresa A et al (2021) Treatment options for elderly\/unfit patients with chronic lymphocytic leukemia in the era of targeted drugs: A comprehensive review. J Clin Med, 10(21)","DOI":"10.3390\/jcm10215104"},{"issue":"29","key":"10834_CR3","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2009.27.8762","volume":"28","author":"T Zenz","year":"2010","unstructured":"Zenz T et al (2010) TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 28(29):4473\u20134479","journal-title":"J Clin Oncol"},{"issue":"1","key":"10834_CR4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/leu.2008.274","volume":"23","author":"F Dicker","year":"2009","unstructured":"Dicker F et al (2009) The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia 23(1):117\u2013124","journal-title":"Leukemia"},{"issue":"21","key":"10834_CR5","doi-asserted-by":"crossref","first-page":"6311","DOI":"10.1158\/0008-5472.CAN-16-0843","volume":"76","author":"J Samuel","year":"2016","unstructured":"Samuel J et al (2016) Posttranscriptional upregulation of p53 by reactive oxygen species in chronic lymphocytic leukemia. Cancer Res 76(21):6311\u20136319","journal-title":"Cancer Res"},{"issue":"11","key":"10834_CR6","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1182\/blood.V91.11.4342","volume":"91","author":"I Cordone","year":"1998","unstructured":"Cordone I et al (1998) 53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood 91(11):4342\u20134349","journal-title":"Blood"},{"issue":"9","key":"10834_CR7","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1182\/blood.V84.9.3158.3158","volume":"84","author":"T Watanabe","year":"1994","unstructured":"Watanabe T et al (1994) The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood 84(9):3158\u20133165","journal-title":"Blood"},{"issue":"3","key":"10834_CR8","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1182\/blood-2005-12-5148","volume":"108","author":"K Kojima","year":"2006","unstructured":"Kojima K et al (2006) Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and May overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 108(3):993\u20131000","journal-title":"Blood"},{"issue":"26","key":"10834_CR9","doi-asserted-by":"crossref","first-page":"40115","DOI":"10.18632\/oncotarget.9499","volume":"7","author":"M Zanjirband","year":"2016","unstructured":"Zanjirband M, Edmondson RJ, Lunec J (2016) Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer. Oncotarget 7(26):40115\u201340134","journal-title":"Oncotarget"},{"issue":"4","key":"10834_CR10","doi-asserted-by":"crossref","first-page":"510","DOI":"10.2174\/156800909788486777","volume":"9","author":"G Zauli","year":"2009","unstructured":"Zauli G et al (2009) Exposure of B cell chronic lymphocytic leukemia (B-CLL) cells to nutlin-3 induces a characteristic gene expression profile, which correlates with nutlin-3-mediated cytotoxicity. Curr Cancer Drug Targets 9(4):510\u2013518","journal-title":"Curr Cancer Drug Targets"},{"issue":"12","key":"10834_CR11","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.3324\/haematol.2018.206631","volume":"104","author":"C Ciardullo","year":"2019","unstructured":"Ciardullo C et al (2019) Non-genotoxic MDM2 Inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells. Haematologica 104(12):2429\u20132442","journal-title":"Haematologica"},{"key":"10834_CR12","doi-asserted-by":"crossref","unstructured":"Aptullahoglu E et al (2025) Targeting the MDM2-p53 interaction with siremadlin: A promising therapeutic strategy for treating TP53 Wild-Type chronic lymphocytic leukemia. Cancers (Basel), 17(2)","DOI":"10.3390\/cancers17020274"},{"issue":"6","key":"10834_CR13","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10637-024-01473-9","volume":"42","author":"S Gungordu","year":"2024","unstructured":"Gungordu S, Aptullahoglu E (2024) Targeting MDM2-mediated suppression of p53 with idasanutlin: a promising therapeutic approach for acute lymphoblastic leukemia. Invest New Drugs 42(6):603\u2013611","journal-title":"Invest New Drugs"},{"issue":"11","key":"10834_CR14","doi-asserted-by":"crossref","first-page":"12951","DOI":"10.18632\/oncotarget.7339","volume":"7","author":"S Trino","year":"2016","unstructured":"Trino S et al (2016) Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients. Oncotarget 7(11):12951\u201312961","journal-title":"Oncotarget"},{"issue":"5","key":"10834_CR15","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1158\/1078-0432.CCR-21-1295","volume":"28","author":"EM Stein","year":"2022","unstructured":"Stein EM et al (2022) Results from a First-in-Human phase I study of Siremadlin (HDM201) in patients with advanced Wild-Type TP53 solid tumors and acute leukemia. Clin Cancer Res 28(5):870\u2013881","journal-title":"Clin Cancer Res"},{"key":"10834_CR16","doi-asserted-by":"crossref","unstructured":"Aptullahoglu E et al (2023) Splicing modulation results in aberrant isoforms and protein products of p53 pathway genes and the sensitization of B cells to Non-Genotoxic MDM2 Inhibition. Int J Mol Sci, 24(3)","DOI":"10.3390\/ijms24032410"},{"issue":"12","key":"10834_CR17","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1038\/s41375-023-02057-x","volume":"37","author":"KB Johansson","year":"2023","unstructured":"Johansson KB et al (2023) Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia. Leukemia 37(12):2356\u20132366","journal-title":"Leukemia"},{"issue":"1","key":"10834_CR18","first-page":"111","volume":"11","author":"A Ghotaslou","year":"2022","unstructured":"Ghotaslou A et al (2022) AMG-232, a new inhibitor of MDM-2, enhance doxorubicin efficiency in Pre-B acute lymphoblastic leukemia cells. Rep Biochem Mol Biol 11(1):111\u2013124","journal-title":"Rep Biochem Mol Biol"},{"issue":"6","key":"10834_CR19","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/s41375-024-02241-7","volume":"38","author":"HL Bell","year":"2024","unstructured":"Bell HL et al (2024) Combination p53 activation and BCL-x(L)\/BCL-2 Inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia. Leukemia 38(6):1223\u20131235","journal-title":"Leukemia"},{"issue":"4","key":"10834_CR20","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/bjc.2017.433","volume":"118","author":"CE Wu","year":"2018","unstructured":"Wu CE et al (2018) Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma. Br J Cancer 118(4):495\u2013508","journal-title":"Br J Cancer"},{"issue":"2","key":"10834_CR21","doi-asserted-by":"crossref","first-page":"242","DOI":"10.20517\/cdr.2022.113","volume":"6","author":"M Zanjirband","year":"2023","unstructured":"Zanjirband M, Rahgozar S, Aberuyi N (2023) miR-16-5p enhances sensitivity to RG7388 through targeting expression (WIP1) in childhood acute lymphoblastic leukemia. Cancer Drug Resist 6(2):242\u2013256","journal-title":"Cancer Drug Resist"},{"issue":"8","key":"10834_CR22","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1158\/2159-8290.CD-23-0419","volume":"13","author":"T Koyama","year":"2023","unstructured":"Koyama T et al (2023) Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an Open-Label phase ib\/ii study. Cancer Discov 13(8):1814\u20131825","journal-title":"Cancer Discov"},{"key":"10834_CR23","doi-asserted-by":"crossref","unstructured":"Daver NG et al (2022) Venetoclax and Idasanutlin in relapsed\/refractory AML: a non-randomized, open-label phase 1b trial. Blood","DOI":"10.1182\/blood.2022016362"},{"issue":"14","key":"10834_CR24","first-page":"4147","volume":"6","author":"MY Konopleva","year":"2022","unstructured":"Konopleva MY et al (2022) Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial. Blood Adv 6(14):4147\u20134156","journal-title":"Blood Adv"},{"issue":"6","key":"10834_CR25","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1158\/1078-0432.CCR-21-1291","volume":"28","author":"AR Abdul Razak","year":"2022","unstructured":"Abdul Razak AR et al (2022) Co-Targeting of MDM2 and CDK4\/6 with Siremadlin and ribociclib for the treatment of patients with Well-Differentiated or dedifferentiated liposarcoma: results from a Proof-of-Concept, phase Ib study. Clin Cancer Res 28(6):1087\u20131097","journal-title":"Clin Cancer Res"},{"key":"10834_CR26","doi-asserted-by":"crossref","unstructured":"Haronikova L et al (2021) Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them? vol 26. Cellular & Molecular Biology Letters, 1","DOI":"10.1186\/s11658-021-00293-6"},{"key":"10834_CR27","doi-asserted-by":"crossref","unstructured":"Aptullahoglu E et al (2023) SF3B1 mutations are associated with resistance to Non-Genotoxic MDM2 Inhibition in chronic lymphocytic leukemia. Int J Mol Sci, 24(14)","DOI":"10.3390\/ijms241411335"},{"key":"10834_CR28","doi-asserted-by":"crossref","first-page":"8778","DOI":"10.1182\/blood-2022-157622","volume":"140","author":"L Savoy","year":"2022","unstructured":"Savoy L et al (2022) Characterize biomarkers and mechanisms of resistance for MDM2 inhibitors in AML. Blood 140:8778\u20138779","journal-title":"Blood"},{"key":"10834_CR29","doi-asserted-by":"crossref","unstructured":"Aptullahoglu E et al (2024) RNA sequencing reveals candidate genes and pathways associated with resistance to MDM2 antagonist Idasanutlin in TP53 Wild-Type chronic lymphocytic leukemia. Biomedicines, 12(7)","DOI":"10.3390\/biomedicines12071388"},{"issue":"1","key":"10834_CR30","doi-asserted-by":"crossref","first-page":"32","DOI":"10.14735\/amko202032","volume":"33","author":"M Boudny","year":"2020","unstructured":"Boudny M, Trbusek M (2020) The important role of STAT3 in chronic lymphocytic leukaemia biology. Klin Onkol 33(1):32\u201338","journal-title":"Klin Onkol"},{"issue":"5","key":"10834_CR31","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1182\/blood.V87.5.1692.1692","volume":"87","author":"V Gouilleux-Gruart","year":"1996","unstructured":"Gouilleux-Gruart V et al (1996) STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood 87(5):1692\u20131697","journal-title":"Blood"},{"issue":"4","key":"10834_CR32","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson DE, O\u2019Keefe RA, Grandis JR (2018) Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat Rev Clin Oncol 15(4):234\u2013248","journal-title":"Nat Rev Clin Oncol"},{"issue":"14","key":"10834_CR33","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1182\/blood-2009-10-230060","volume":"115","author":"I Hazan-Halevy","year":"2010","unstructured":"Hazan-Halevy I et al (2010) STAT3 is constitutively phosphorylated on Serine 727 residues, binds DNA, and activates transcription in CLL cells. Blood 115(14):2852\u20132863","journal-title":"Blood"},{"issue":"12","key":"10834_CR34","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1172\/JCI119869","volume":"100","author":"DA Frank","year":"1997","unstructured":"Frank DA, Mahajan S, Ritz J (1997) B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on Serine residues. J Clin Invest 100(12):3140\u20133148","journal-title":"J Clin Invest"},{"issue":"Pt 2","key":"10834_CR35","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1042\/BJ20050465","volume":"392","author":"S Bhattacharya","year":"2005","unstructured":"Bhattacharya S, Ray RM, Johnson LR (2005) STAT3-mediated transcription of Bcl-2, Mcl-1 and c-IAP2 prevents apoptosis in polyamine-depleted cells. Biochem J 392(Pt 2):335\u2013344","journal-title":"Biochem J"},{"issue":"11","key":"10834_CR36","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1182\/blood-2018-01-829424","volume":"132","author":"TL Song","year":"2018","unstructured":"Song TL et al (2018) Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer\/T-cell lymphoma. Blood 132(11):1146\u20131158","journal-title":"Blood"},{"issue":"11","key":"10834_CR37","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.4049\/jimmunol.1900389","volume":"203","author":"U Rozovski","year":"2019","unstructured":"Rozovski U et al (2019) STAT3-Induced Wnt5a provides chronic lymphocytic leukemia cells with survival advantage. J Immunol 203(11):3078\u20133085","journal-title":"J Immunol"},{"issue":"6","key":"10834_CR38","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1073\/pnas.1424171112","volume":"112","author":"Y Li","year":"2015","unstructured":"Li Y et al (2015) Suppression of cancer relapse and metastasis by inhibiting cancer stemness. Proc Natl Acad Sci U S A 112(6):1839\u20131844","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10834_CR39","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.canlet.2018.04.008","volume":"428","author":"L MacDonagh","year":"2018","unstructured":"MacDonagh L et al (2018) BBI608 inhibits cancer stemness and reverses cisplatin resistance in NSCLC. Cancer Lett 428:117\u2013126","journal-title":"Cancer Lett"},{"issue":"6","key":"10834_CR40","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/cam4.675","volume":"5","author":"Y Zhang","year":"2016","unstructured":"Zhang Y et al (2016) Suppression of prostate cancer progression by cancer cell stemness inhibitor Napabucasin. Cancer Med 5(6):1251\u20131258","journal-title":"Cancer Med"},{"issue":"4","key":"10834_CR41","first-page":"1069","volume":"109","author":"L Gasparoli","year":"2024","unstructured":"Gasparoli L et al (2024) Susceptibility of pediatric acute lymphoblastic leukemia to STAT3 Inhibition depends on p53 induction. Haematologica 109(4):1069\u20131081","journal-title":"Haematologica"},{"issue":"17","key":"10834_CR42","first-page":"4827","volume":"48","author":"DA Scudiero","year":"1988","unstructured":"Scudiero DA et al (1988) Evaluation of a soluble tetrazolium\/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 48(17):4827\u20134833","journal-title":"Cancer Res"},{"issue":"3","key":"10834_CR43","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","volume":"20","author":"S Zheng","year":"2022","unstructured":"Zheng S et al (2022) SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets. Genomics Proteom Bioinf 20(3):587\u2013596","journal-title":"Genomics Proteom Bioinf"},{"key":"10834_CR44","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","volume":"13","author":"B Yadav","year":"2015","unstructured":"Yadav B et al (2015) Searching for drug synergy in complex Dose-Response landscapes using an interaction potency model. Comput Struct Biotechnol J 13:504\u2013513","journal-title":"Comput Struct Biotechnol J"},{"key":"10834_CR45","doi-asserted-by":"crossref","first-page":"100110","DOI":"10.1016\/j.crphar.2022.100110","volume":"3","author":"D Duarte","year":"2022","unstructured":"Duarte D, Vale N (2022) Evaluation of synergism in drug combinations and reference models for future orientations in oncology. Curr Res Pharmacol Drug Discov 3:100110","journal-title":"Curr Res Pharmacol Drug Discov"},{"issue":"5762","key":"10834_CR46","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1126\/science.1115035","volume":"311","author":"SA Lakhani","year":"2006","unstructured":"Lakhani SA et al (2006) Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. Science 311(5762):847\u2013851","journal-title":"Science"},{"issue":"8","key":"10834_CR47","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/bies.20085","volume":"26","author":"JC Ame","year":"2004","unstructured":"Ame JC, Spenlehauer C, de Murcia G (2004) The PARP Superfamily Bioessays 26(8):882\u2013893","journal-title":"The PARP Superfamily Bioessays"},{"key":"10834_CR48","doi-asserted-by":"crossref","first-page":"106489","DOI":"10.1016\/j.leukres.2020.106489","volume":"100","author":"K Yee","year":"2021","unstructured":"Yee K et al (2021) Murine double minute 2 Inhibition alone or with cytarabine in acute myeloid leukemia: results from an Idasanutlin phase 1\/1b study small star, filled. Leuk Res 100:106489","journal-title":"Leuk Res"},{"issue":"12","key":"10834_CR49","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1158\/1535-7163.MCT-23-0783","volume":"23","author":"A Gollner","year":"2024","unstructured":"Gollner A et al (2024) Discovery and characterization of brigimadlin, a novel and highly potent MDM2-p53 antagonist suitable for intermittent dose schedules. Mol Cancer Ther 23(12):1689\u20131702","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"10834_CR50","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/neuonc\/noac271","volume":"25","author":"X Hao","year":"2023","unstructured":"Hao X et al (2023) BI-907828, a novel potent MDM2 inhibitor, inhibits glioblastoma brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models. Neuro Oncol 25(5):913\u2013926","journal-title":"Neuro Oncol"},{"issue":"8","key":"10834_CR51","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1158\/2159-8290.CD-23-0153","volume":"13","author":"P LoRusso","year":"2023","unstructured":"LoRusso P et al (2023) The MDM2-p53 antagonist Brigimadlin (BI 907828) in patients with advanced or metastatic solid tumors: results of a phase ia, First-in-Human, Dose-Escalation study. Cancer Discov 13(8):1802\u20131813","journal-title":"Cancer Discov"},{"issue":"17","key":"10834_CR52","doi-asserted-by":"crossref","first-page":"7432","DOI":"10.1128\/MCB.25.17.7432-7440.2005","volume":"25","author":"G Niu","year":"2005","unstructured":"Niu G et al (2005) Role of Stat3 in regulating p53 expression and function. Mol Cell Biol 25(17):7432\u20137440","journal-title":"Mol Cell Biol"},{"key":"10834_CR53","doi-asserted-by":"crossref","unstructured":"Yu HY et al (2014) LIF negatively regulates tumour-suppressor p53 through Stat3\/ID1\/MDM2 in colorectal cancers. Nat Commun, 5","DOI":"10.1038\/ncomms6218"},{"issue":"22","key":"10834_CR54","doi-asserted-by":"crossref","first-page":"32031","DOI":"10.18632\/oncotarget.8672","volume":"7","author":"FT Liu","year":"2016","unstructured":"Liu FT et al (2016) STAT3 and NF-kappaB cooperatively control in vitro spontaneous apoptosis and poor chemo-responsiveness in patients with chronic lymphocytic leukemia. Oncotarget 7(22):32031\u201332045","journal-title":"Oncotarget"},{"issue":"3","key":"10834_CR55","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1172\/JCI9940","volume":"107","author":"PK Epling-Burnette","year":"2001","unstructured":"Epling-Burnette PK et al (2001) Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 107(3):351\u2013362","journal-title":"J Clin Invest"},{"issue":"4","key":"10834_CR56","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.yexcr.2012.11.005","volume":"319","author":"DW Kulesza","year":"2013","unstructured":"Kulesza DW et al (2013) Silencing of the transcription factor STAT3 sensitizes lung cancer cells to DNA damaging drugs, but not to TNFalpha- and NK cytotoxicity. Exp Cell Res 319(4):506\u2013516","journal-title":"Exp Cell Res"},{"key":"10834_CR57","doi-asserted-by":"crossref","unstructured":"Langleben A et al (2013) A dose-escalation phase I study of a first-in-class cancer stemness inhibitor in patients with advanced malignancies. J Clin Oncol, 31(15)","DOI":"10.1200\/jco.2013.31.15_suppl.2542"},{"key":"10834_CR58","doi-asserted-by":"crossref","unstructured":"Bekaii-Saab TS et al (2017) A phase ib\/ii study of cancer sternness inhibitor Napabucasin (BBI-608) in combination with gemcitabine (gem) and nab-paclitaxel (nabPTX) in metastatic pancreatic adenocarcinoma (mPDAC) patients (pts). J Clin Oncol, 35","DOI":"10.1200\/JCO.2017.35.15_suppl.4106"},{"issue":"22","key":"10834_CR59","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.1158\/1078-0432.CCR-20-1803","volume":"26","author":"A Kawazoe","year":"2020","unstructured":"Kawazoe A et al (2020) Multicenter phase I\/II trial of Napabucasin and pembrolizumab in patients with metastatic colorectal Cancer (EPOC1503\/SCOOP trial). Clin Cancer Res 26(22):5887\u20135894","journal-title":"Clin Cancer Res"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10834-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-10834-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10834-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T04:26:22Z","timestamp":1766895982000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-10834-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10834"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-10834-3","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"type":"print","value":"0301-4851"},{"type":"electronic","value":"1573-4978"}],"subject":[],"published":{"date-parts":[[2025,7,17]]},"assertion":[{"value":"2 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"731"}}